论文部分内容阅读
目的:探讨诱导痰液趋化因子在哮喘儿童气道炎症及哮喘病情评价中的意义。方法:90例哮喘患儿作为研究对象,20例健康体检儿童作为对照组。所有研究对象均进行痰液诱导及诱导痰细胞学分析,ELISA法检测痰液调节正常T细胞表达和分泌活性因子(RANTES)、嗜酸性粒细胞趋化蛋白-2(Eotaxin-2)、白细胞介素-8(IL-8)、单核细胞趋化蛋白-1(MCP-1),儿童肺功能仪检测基础肺功能。应用SPSS13.0软件进行统计学分析。结果:①哮喘患儿诱导痰液趋化因子RAN-TES、Eotaxin-2、IL-8、MCP-1水平高于健康对照组,两组比较差异有统计学意义(P<0.05)。②哮喘患儿急性发作期诱导痰RANTES、Eotaxin-2水平高于缓解期,两者比较差异有统计学意义(P<0.05)。③重度发作哮喘组IL-8、MCP-l水平高于轻～中度发作哮喘组,两组差异有统计学意义(P<0.05)。结论:哮喘患儿诱导痰趋化因子RANTES、Eotaxin-2与哮喘急性发作和气道高反应性有关,而诱导痰IL-8、MCP-1与哮喘病情加重及肺功能恶化有关。动态检测哮喘患儿诱导痰中趋化因子变化,将有助于哮喘病情监控和哮喘的个体化治疗方案的制定。
Objective: To investigate the significance of induced sputum chemokines in the evaluation of airway inflammation and asthma in asthmatic children. Methods: Totally 90 children with asthma were selected as research subjects and 20 healthy children as control group. All subjects were sputum induced sputum cytology and induced sputum, normal sputum T regulate the expression and secretion of active factors (RANTES), eotaxin-2 (Eotaxin-2), interleukin (IL-8), monocyte chemoattractant protein-1 (MCP-1), and children’s lung function test. Application SPSS13.0 software for statistical analysis. Results: ① The levels of chemotactic factors RAN-TES, Eotaxin-2, IL-8 and MCP-1 in induced sputum in asthmatic children were significantly higher than those in healthy controls (P <0.05). ② The levels of RANTES and Eotaxin-2 in induced sputum in acute stage of asthma children were higher than those in remission stage, the difference was statistically significant (P <0.05). ③ Severe seizures asthma group IL-8, MCP-l levels were higher than mild to moderate asthma attack group, the difference between the two groups was statistically significant (P <0.05). CONCLUSIONS: The sputum chemokines RANTES and Eotaxin-2 induced by asthma in children are related to acute asthma attack and airway hyperresponsiveness. The induced sputum IL-8 and MCP-1 are related to the exacerbation of asthma and the deterioration of pulmonary function. The dynamic detection of chemotactic changes induced in sputum in children with asthma will contribute to the development of individualized treatment plans for asthma surveillance and asthma.